

NCCN Drugs & Biologics Compendium

(NCCN Compendium®)

Access to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for non-commercial users is available via subscription.

Prior to accessing the NCCN Compendium®, users must accept an End-User License Agreement (EULA) and create a free account or login with an existing account on NCCN.org.

About the NCCN Compendium®

Based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Compendium contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer.

The recommendations for appropriate use of drugs and biologics contained in the NCCN Compendium are extracted directly from the relevant NCCN Guidelines® along with their clinical context, route of administration, recommended use, and NCCN Category of Evidence. NCCN staff pharmacists generate the NCCN Compendium at the agent level rather than regimen; however, these agents reflect the components of regimens used in disease management. In addition to Guidelines-specific indication and use, NCCN adds relevant information such as pharmacologic class, relevant ICD-10 codes, and U.S. Food and Drug Administration (FDA) indication to the searchable database. Compendium development and maintenance is accomplished by disease site and reviewed by members of the relevant NCCN Guidelines Panel before publication.

The NCCN Compendium is recognized by public and private insurers alike, including, but not limited to the Centers for Medicare and Medicaid Services (CMS) and UnitedHealthcare, as an authoritative reference for oncology coverage policy. Managed care medical directors, pharmacy benefits directors, and other health care professionals also reference the NCCN Compendium when making decisions that impact patient access to appropriate therapy. The uses identified are based upon evaluation of evidence from scientific literature integrated with expert judgment in an evidence-based process. Indicated uses are categorized in a systematic approach that describes the type of evidence available for and the degree of consensus underlying each recommendation. All recommendations (at all category levels) in the NCCN Compendium constitute appropriate, medically necessary care. The NCCN Compendium lists both FDA-approved uses and appropriate uses beyond the FDA-approved label.

The NCCN Compendium is accessible through an easy-to-use web-based user interface and includes a full complement of drugs and biologics recommendations found in the currently published Guidelines. The NCCN Compendium is reviewed on a continual basis to ensure that the recommendations take into account the most current evidence.

[NCCN.org/professionals/drug_compendium](https://www.nccn.org/professionals/drug_compendium)

1 The top menu of the NCCN Compendium contains various drop-down lists for displaying the database.

Options

Use the drop-down menus to search the database:

Guideline: -- Select a NCCN Guideline --

Disease: -- Select a Disease Setting --

Agent: -- Select an Agent --

Brand: -- Select a Brand --

Route: -- Select a Route --

NCCN Category of Evidence: -- Select a Category --

Histology: -- Select a Histology --

ICD-10: -- Select an ICD-10 Code --

Billing Code: -- Select a Billing Code --

Reset Filters Print 0 Ready to Print

No Longer Recommended Uses

Transparency, Process and Recommendations

Filters: Select a Guideline

Default Sort Showing 0 to 0 of 0 entries Search:

Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Order Template	FDA Indication	Billing Code
---------------------	-------	-------	---------------------	-----------	----------	--------------	----------------------	---------------	----------------	----------------	--------------

No information available. Use the filters to narrow your search.

▲
An easy-to-read view of the selected compendium entries can be made available for printing or saving as a PDF by checking the box in the left most column.

2

To display the content of your choice, select any item from the drop-down menus. You can start with any of the menus and choose from the available options in one or multiple lists.

NCCN National Comprehensive Cancer Network® NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: -- Select a NCCN Guideline --

Disease: -- Select a NCCN Guideline --

Agent: -- Select a NCCN Guideline --

Brand: -- Select a NCCN Guideline --

Route: -- Select a NCCN Guideline --

Acute Lymphoblastic Leukemia v.1.2018
Acute Myeloid Leukemia v.3.2018
AIDS-Related Kaposi Sarcoma v.2.2019
Anal Carcinoma v.2.2018
Antiemesis v.3.2018
Basal Cell Skin Cancer v.1.2019
B-Cell Lymphomas v.1.2019
Bladder Cancer v.1.2019
Bone Cancer v.1.2019
Breast Cancer Risk Reduction v.1.2019
Breast Cancer v.3.2018
Cancer- and Chemotherapy-Induced Anemia v.3.2018
Cancer-Associated Venous Thromboembolic Disease v.2.2018
Central Nervous System Cancers v.2.2018
Cervical Cancer v.3.2019
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma v.2.2019
Chronic Myeloid Leukemia v.1.2019
Colon Cancer v.4.2018

NCCN National Comprehensive Cancer Network® NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: Breast Cancer v.3.2018

Disease: Breast Cancer - Invasive Breast Cancer

Agent: -- Select a Disease Setting --

Brand: -- Select a Brand --

Route: -- Select a Route --

Breast Cancer - Breast Cancer During Pregnancy
Breast Cancer - Ductal Carcinoma In situ
Breast Cancer - Invasive Breast Cancer

Reset Filters Print 0 Ready to Print

If you continue to filter the database using additional drop-down menus, they will automatically adjust to narrow down the available options based on each of your previous selections.

NCCN National Comprehensive Cancer Network® NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: Breast Cancer v.3.2018

Disease: Breast Cancer - Invasive Breast Cancer

Agent: -- Select a Agent --

Brand: -- Select a Agent --

Route: -- Select a Agent --

Abemaciclib
Ado-trastuzumab emtansine
Anastrozole
Bevacizumab
Capecitabine
Carboplatin
Cisplatin
Cyclophosphamide
Denosumab
Docetaxel
Doxorubicin hydrochloride
Doxorubicin hydrochloride liposome
Epirubicin hydrochloride
Eribulin

Filters: Breast Cancer v.3.2018

NCCN National Comprehensive Cancer Network® NCCN Drugs & Biologics Compendium®

Options

Use the drop-down menus to search the database:

Guideline: Breast Cancer v.3.2018

Disease: Breast Cancer - Invasive Breast Cancer

Agent: Gemcitabine hydrochloride

Brand: -- Select a Brand --

Route: -- Select a Brand --

Gemzar®

Reset Filters Print 0 Ready to Print

Filters: Breast Cancer v.3.2018 > Breast Cancer - Invasive Breast Cancer > Gemcitabine hydrochloride

3 The data table will display default data fields, including: Guideline, Disease, Agent, Brand, Pharmacologic Class, Histology, Route(s), ICD-10 Codes, Billing Code, NCCN Recommended Use, NCCN Category of Evidence, Chemotherapy Order Template(s), and FDA approved indication(s).

The Guideline hyperlink will lead to the front page of the NCCN Guidelines where users can navigate to the appropriate page.

The Brand name hyperlink will lead to the most recent prescribing information (also known as the label or package insert) posted on the FDA website.

The Panel Disclosure hyperlink will lead to the list of current panel members and their most recent disclosure(s) for the associated NCCN Guidelines.

Hovering over the chemotherapy order template acronym will display the full name of the regimen. Click on the hyperlink to view the chemotherapy order template associated with the compendium entry.

Hovering over the NCCN Category will display more information about what each category represents. Compendium entries may contain multiple recommendations that each correspond to different categories of evidence.

Options

Use the drop-down menus to search the database:

Guideline: Cervical Cancer v.3.2019

Disease: Cervical Cancer

Agent: Gemcitabine hydrochloride

Brand: Gemzar®

Route(s):

NCCN Category of Evidence: -- Select a Category --

Histology: -- Select a Histology --

ICD-10: -- Select an ICD-10 Code --

Billing Code: -- Select a Billing Code --

No Longer Recommended Uses

Transparency: Process and Recommendations

Search:

Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Order Template	FDA Indication	Billing Code
Gemcitabine hydrochloride	Gemzar®	Antimetabolite: Pyrimidine antagonist	Adenocarcinoma, Squamous cell carcinoma	IV	C53.0, C53.1, C53.8, C53.9, C79.89, C79.9	Second-line therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage I/IV or distant metastases 	2B	CRV20	Ovarian Cancer: Gemcitabine	J9201

Filters: Cervical Cancer v.3.2019 > Cervical Cancer > Gemcitabine hydrochloride > Gemzar®

Default Sort Showing 1 to 1 of 1 entries

Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Order Template	FDA Indication	Billing Code
Cervical Cancer - Cervical Cancer Guideline Panel Disclosure	Gemcitabine hydrochloride	Gemzar®	Antimetabolite: Pyrimidine antagonist	Adenocarcinoma, Squamous cell carcinoma	IV	C53.0, C53.1, C53.8, C53.9, C79.89, C79.9	Second-line therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage I/IV or distant metastases 	2B	CRV20	Ovarian Cancer: Gemcitabine hydrochloride in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. Breast Cancer: Gemcitabine hydrochloride in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after	J9201

Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate

4

The NCCN Compendium is built on a responsive platform that can be viewed on mobile devices. If the screen size cannot accommodate all data fields simultaneously, the interface will automatically hide certain fields and indicate this with a red numbered icon in the left most column of the data table.

Filters: [Cervical Cancer v.3.2019](#) > [Cervical Cancer](#) > [Gemcitabine hydrochloride](#) > [Gemzar®](#)

Default Sort Showing 1 to 1 of 1 entries Search:

	Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Order Template
	Cervical Cancer - Cervical Cancer Guideline Panel	Gemcitabine hydrochloride	Gemzar®	Antimetabolite: Pyrimidine antagonist	Adenocarcinoma, Squamous cell carcinoma	IV	C53.0, C53.1, C53.8, C53.9, C79.89, C79.9	Second-line therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage IVB or distant metastases 	2B	CRV20

▲
A red numbered icon indicates hidden fields when viewed on mobile devices, tablets, or reduced screen sizes. Click on the icon to view additional fields in a vertical display.

5

With the desired content displayed, individual or multiple records may be selected for printing by checking the printer icon box (left-most data field).

Printer icon

Reset Filters



1 Ready to Print

No Longer Recommended Uses

Transparency: Process and Recommendations

Filters: Cervical Cancer v.3.2019 > Cervical Cancer > Gemcitabine hydrochloride > Gemzar®

Default Sort

Showing 1 to 1 of 1 entries

Search:

	Guideline - Disease	Agent	Brand	Pharmacologic Class	Histology	Route(s)	ICD-10 Codes	NCCN Recommended Use	NCCN Category	Order Template
<input checked="" type="checkbox"/>	Cervical Cancer - Cervical Cancer Guideline Panel Disclosure	Gemcitabine hydrochloride	Gemzar®	Antimetabolite: Pyrimidine antagonist	Adenocarcinoma, Squamous cell carcinoma	IV	C53.0, C53.1, C53.8, C53.9, C79.89, C79.9	Second-line therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage IVB or distant metastases 	2B	CRV20

Print Record(s)...

Save as PDF...

Print the page or save the record as a PDF.



NCCN Drugs & Biologics Compendium®

Printed by Briana O'Donnell on 1/14/2019 3:09 PM. For personal use only. Not approved for distribution. The NCCN Drugs & Biologics Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/DrugCompendium.

Disease Information

Guideline Name:	Cervical Cancer 3.2019
Disease:	Cervical Cancer
Agent:	Gemcitabine hydrochloride
FDA Indication:	Ovarian Cancer: Gemcitabine hydrochloride in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. Breast Cancer: Gemcitabine hydrochloride in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. Non-Small Cell Lung Cancer: Gemcitabine hydrochloride is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (stage IIA or IIIB), or metastatic (stage IV) non-small cell lung cancer. Pancreatic Cancer: Gemcitabine hydrochloride is indicated as first-line treatment for patients with locally advanced (nonresectable stage II or stage III) or metastatic (stage IV) adenocarcinoma of the pancreas. Gemcitabine hydrochloride is indicated for patients previously treated with fluorouracil.
Brand:	Gemzar®
Category of Evidence:	2B
Histology:	Squamous cell carcinoma, Adenocarcinoma
Pharmacologic Class:	Antimetabolite: Pyrimidine antagonist
Route:	IV
Recommended:	Second-line therapy as a single agent for <ul style="list-style-type: none"> local/regional recurrence stage IVB or distant metastases
ICD10:	C53.0, C53.1, C53.8, C53.9, C79.89, C79.9

6

Information regarding No Longer Recommended Uses and the Transparency documents for each update of the NCCN Guidelines® and associated Compendium chapter(s) is available by clicking on the options at the top of the Compendium display.

The screenshot shows the top section of the NCCN Drugs & Biologics Compendium interface. On the left, there are several dropdown menus for filtering: Guideline, Disease, Agent, Brand, and Route. On the right, there are dropdown menus for NCCN Category of Evidence, Histology, ICD-10, and Billing Code. Below these filters are buttons for 'Reset Filters', 'Print', and '0 Results'. Two callout boxes are present: one on the right pointing to a 'No Longer Recommended Uses' button, and one in the center pointing to a 'Transparency: Process and Recommendations' button.

“No Longer Recommended Uses” is a list of archived compendium entries that describe drugs and biologics previously (but no longer) recommended in the associated NCCN Guidelines.

The Transparency: Process and Recommendations page lists the NCCN Guidelines updates by version and year, panel meeting date(s), attendance, evidence reviewed during the meeting, and the outcome of any discussions and voting that took place. A link to the panel disclosures at the time of the update is also available for each transparency posting.